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ABSTRACT
Introduction: The purpose of this study was to
explore the main factors explaining the relative
weight of the different attributes that determine
the value of oncologic treatments from the
different perspectives of healthcare policy
makers (HCPM), oncologists, patients and the
general population in Spain.
Methods: Structured interviews were
conducted to assess: (1) the importance of the
attributes on treatment choice when comparing
a new cancer drug with a standard cancer
treatment; (2) the importance of survival,
quality of life (QoL), costs and innovation in
cancer; and (3) the most worrying side effects
related to cancer drugs.
Results: A total of 188 individuals participated
in the study. For all participants, when
choosing treatments, the best rated
characteristics were greater efficacy, greater
safety, treatment adaptation to patients’
individual requirements and the rapid
reincorporation of patients to their daily
activities. There were important differences
among participants in their opinion about
survival, QoL and cost. In general, oncologists,
patients, and the general population gave
greater value to gains in QoL than healthcare
policy makers. Compared to other participants
healthcare policy makers gave greater
importance to the economic impact related to
oncology treatments.
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Conclusions: Gains in QoL, survival, safety,
cost and innovation are perceived differently
by different groups of stakeholders. It is
recommended to consider the perspective of
different stakeholders in the assessment of a
new cancer drugs to obtain more informed
decisions when deciding on the most
appropriate treatment to use.
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INTRODUCTION
Cancer is one of the leading causes of morbidity
and mortality worldwide, with 14.1 million new
cancer cases and 8.2 million cancer deaths [1]. It
is estimated that within two decades, cancer
rates will double to approximately 22 million
cases [2]. Regardless of this increase in the
number of new cancer cases each year,
patients’ survival has improved due to the
drugs that are currently available, together
with the progress of cancer prevention and
diagnostics [2].
The study and understanding of molecular
mechanisms related to cancer has allowed
identifying and developing novel target
treatments. Some new therapies delay tumor
growth, opening up the prospect for patients’
long-term survival and turning cancer into a
chronic disease [3]. At the same time,
expenditure on cancer drugs has grown
steadily [4]. It has been argued that the high
cost of contemporary cancer drugs may signal
even greater costs for future drugs [5].
Consequently, the debates regarding the rise
of healthcare costs and the development and
value of new medical technologies are
increasingly present.
In today’s economic context, governments
have the challenge to provide high quality and
innovative care to meet the population’s health
needs most effectively while managing health
care budgets and safeguarding the basic
principles of equity, access and choice. For this
reason, to control healthcare costs,
governments need to apply evidence-based
principles in evaluating the new medicines,
often using ‘‘additional cost per additional
health benefit’’ to measure ‘‘value for money’’
[6].
Currently, there is intense debate regarding
the value considerations of new cancer drugs.
The American Society of Clinical Oncology
(ASCO) has proposed a conceptual framework
to assess the value of cancer treatment options
through their clinical benefits (efficacy),
toxicity (safety) and cost (efficiency) [7].
Moreover, the European Society for Medical
Oncology (ESMO) has undertaken the
development of a validated and reproducible
tool to assess the magnitude of the clinical
benefits of anti-cancer interventions, the ESMO
Magnitude of Clinical Benefit Scale
(ESMO-MCBS) [8]. There is a growing need to
define and adopt explicit decision criteria in the
choice of new cancer drugs, and there is an
agreement on the need to consider the opinions
and preferences of the society. Although the
definition and adoption of explicit decision
criteria in the choice of new cancer drugs is a
major breakthrough, it is important to note that
the assessment of the value of any cancer
treatment (efficacy, safety, quality of life, cost)
may be different depending on healthcare
systems and stakeholders. Therefore, decisions
related to resource allocation should reflect the
opinion and preferences of the society.
Including citizen input in government
priority-setting approaches is becoming more
relevant and there is growing demand for
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governments to make resource allocation
decisions in line with social values. Some
studies have reported that in general, citizens
and payers priorities for funding a new cancer
drugs are different. Payers prioritize efficiency
defined as health gains per dollar, while general
population or patients prioritize equity
understood as equal access to medicines
independent of cost or effectiveness [9].
Understanding the value of a new cancer
drug from different perspectives, including
those of the general population and patients,
can provide insight regarding the factors that
should determine the value of new oncologic
treatments. The objective of this work was to
conduct an exploratory and qualitative study to
investigate the main factors that drive
innovation in oncology, and to determine the
importance of each attribute from different
perspectives: healthcare policy makers,
oncologists, patients and the general
population in Spain.
METHODS
Study Participants
Oncologists, healthcare policy makers, patients
and the general population were invited to
participate in the study. Oncologists working in
the Spanish National Health System and with
more than 10 years of professional experience;
and healthcare policy makers with at least one
political legislative period of experience at local
regional or national level were selected to
participate in the study. In order to assure that
all participants were able to understand the
questionnaire and willing to participate in the
study, a convenience sample of the general
population was used. This sample included
employees of technology companies, research
institutes, universities and governmental
institutions. Finally, patients were contacted
through local cancer associations and the
Spanish Cancer Federation. New participants
were contacted until saturation of information
was reached [10].
Confidentiality was assured to all the
participants in the study, and no incentives
were offered for completing the questionnaire.
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013. Given the study’s nature, it did not
require approval by an Ethics Committee.
Structured Interview
The structured interview was carried out by two
interviewers between December 2013 and
February 2014. Interviewers were trained and
followed an interview guide which provided a
clear set of instructions for interviewers in order
to provide reliable, comparable qualitative data.
The interview guide included three sections.
Section 1 explored the importance of attributes
on treatment choice, when comparing a new
cancer drug with a standard cancer treatment.
The responses were based on a 5-point Likert
scale (‘‘Not important’’ to ‘‘Very Important’’).
Section 2 included 16 statements related to the
importance of survival, quality of life (QoL),
costs and innovation in cancer treatment.
Participants responded based on a 5-point
Likert scale (1 ‘‘I absolutely disagree’’, 2 ‘‘I
disagree’’, 3 ‘‘I am undecided’’, 4 ‘‘I agree’’, 5 ‘‘I
absolutely agree’’). Section 3 brought out the
most worrying side effects related to cancer
drugs. In this section, participants selected the
three most worrying side effects from a list of
the most common side effects related to cancer
drugs, including nausea, dizziness, vomiting,
Adv Ther (2016) 33:2059–2068 2061
pain, fatigue, hair loss, diarrhea, infection and
rash [11, 12]. During the interview, general
information about the respondents was also
collected.
Results from two hypothetical
decision-making scenarios (a life-prolonging
scenario and a QoL-enhancing scenario)
included in the study are published elsewhere
[13].
Data Analysis
A descriptive analysis was conducted using SPSS
v.19 (IBM Corp, Armonk, NY, USA). The
percentage of each response based on a
5-point Likert scale in sections 1 and 2 was
estimated. For section 3, the percentage of
patients that selected each side effect was
calculated.
RESULTS
Participant Characteristics
The qualitative convenience sample included a
total of 188 individuals: 53 oncologists, 25
healthcare policy makers, 60 patients and 50
individuals from the general population [13].
Importance of the Attributes of New Cancer
Drugs on Treatment Choice
These results are shown in Table 1.
For the total sample, when choosing
treatments, the characteristics most highly
rated by participants were greater efficacy
(defined as increases in survival), greater safety
(described as fewer or less severe side effects),
improvements in QoL, adaptation of treatment
to patients’ individual requirements, and
patients’ rapid reincorporation to their daily
activities. In almost all study groups, the
percentages of ‘‘important’’ or ‘‘very
important’’ responses were above 80.0%. It is
important to note that for the four study
groups, greater efficacy was the highest rated
treatment characteristic.
On the other hand, treatment features such
oral rather than intravenous administration,
potential direct cost savings (reduction of
inpatient admissions) and potential indirect
cost savings (improvement in work
productivity) were less rated (\80% of patients
considered these characteristics ‘‘important’’ or
‘‘very important’’). Compared to other study
participants, more healthcare policy makers
considered the attributes ‘‘treatment
characteristics related to direct cost saving’’
and ‘‘lower cost’’ as being ‘‘important’’ or ‘‘very
important’’ (88% and 72%, respectively).
Perceived Innovation of New Cancer Drugs
In order to assess perceived innovation of new
cancer drugs, participants responded to 14
statements based on a 5-point Likert scale. The
results showed that gains in survival and in QoL
were key features of innovative oncology
treatments. Table 2 shows the responses
obtained in the 14 statements that evaluate
the importance of the improvement in survival,
safety, QoL and cost gained with new cancer
drugs, and their contribution to innovation for
the four study groups.
Regarding the questions related to survival,
the healthcare policy makers group scored
lowest. Therefore, compared to the rest of
participants, healthcare policy makers
considered that an additional improvement of
1-month survival associated to a new cancer
drug (when the standard treatment provides 3
months’ survival) would not be relevant.
Similarly, a lower proportion of healthcare
policy makers considered that when selecting
treatment, the most important attribute was
that the cancer drug provided additional
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survival despite increasing the risk of side
effects.
Related to QoL, most patients and general
population subjects agreed strongly or
somewhat as to the importance of achieving
gains in QoL, despite the new treatment not
lengthening survival; while half of the
healthcare policy makers and oncologists were
of a similar opinion.
Most study participants agreed that patients
should receive information regarding the
budgetary impact of cancer treatment, even
though they do not have to pay for it. Although
most study participants agreed strongly or
somewhat that the cost of a new treatment
influences their approval and/or their choice of
clinical practice, only half of patients agreed
with this statement. Moreover, only a small
proportion of the patients and the general
population subjects considered that, when
prescribing a cancer treatment, the oncologists
should take economic aspects into account
when choosing a particular treatment. Despite
the fact that almost all study participants
considered that every patient should have
access to effective cancer treatments regardless
of cost, only half of the healthcare policy
makers agreed strongly or somewhat with this.
Importance of Side Effects Related to Cancer
Drugs
The most worrying side effects were serious
infections due to the compromised immune
system imposed by oncology treatments, pain
Table 1 Importance of different attributes on treatment choice
Attribute of a new cancer drug % of participants that consider the attribute ‘‘important’’ or ‘‘very important’’
Oncologist
(n 5 53)
Healthcare policy
maker (n5 25)
Patients
(n5 60)
General population
(n 5 50)
Greater efﬁcacy (increased survival) 100.0 100.0 100.0 98.0
Greater safety (fewer or less severe side
effects)
100.0 96.0 90.0 98.0
Improvement in health-related quality
of life
98.1 84.0 100.0 96.0
Treatment adaptation to patients’
clinical requirements
100.0 80.0 96.7 88.0
Rapid reincorporation of patients to
their daily activities
96.2 80.0 78.3 90.0
Oral rather than intravenous
administration
60.4a 56.0 60.0a 66.0
Direct cost savings (reduction of
hospital admissions)
77.4 88.0 73.3 66.0
Lower cost 56.6 72.0 50.0 44.0
Indirect cost savings (work productivity
improvement)
58.5 52.0 53.3 58.0
a Differences related to the proportion of participants that considered the attribute ‘‘slightly important’’ or ‘‘not important’’
were detected: oncologists 3.77%; healthcare policy makers 6.0%, patients 15.7% and general population 8.0%
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Table 2 Opinion on statements related to survival, health-related quality of life, cost and innovation
Statement % of participants stating ‘‘I agree’’ or ‘‘I absolutely agree’’
Oncologist
(n 5 53)
Healthcare
policy maker
(n5 25)
Patients
(n5 60)
General
population
(n5 50)
Survival
If the standard treatment for cancer provides 3 months’
survival, a drug that extends life 1 more month is relevant
54.7 28.0 58.3 62.0
At the time of treatment choice, the most important
attribute is that it provides additional survival, although it
increases the risk of side effects
39.6 16.0 50.0 44.0
Health-related quality of life
During treatment choice, the most important attribute is
that it improves the health-related quality of life, although
it does not provide additional survival
56.6 44.0 68.3 72.0
Cost
It is important that patients should know the economic
impact of treatments, even though they do not have to
pay for them
79.2 88.0 78.3 84.0
The costs of new cancer drugs inﬂuence treatment choice
and/or approval
84.9 88.0 56.7 72.0
Every patient should have access to effective cancer
treatments regardless of their costs
96.2 56.0 98.3 100.0
The oncologists should consider the economic aspects
when choosing a particular treatment
71.7 100.0 10.0 34.0
In the next 5 years, the costs of new cancer drugs will play
a signiﬁcant role in treatment recommendations
88.7 100.0 30.0 56.0
Innovation
New cancer drugs developed in the past decade have
yielded signiﬁcant innovations
96.2 88.3 92.0 86.0
Innovation provided by a new cancer drug is due to its
improvement on quality of life
90.6 80.0 90.0 88.0
Innovation provided by a new cancer drug is due to its
improvement on survival
98.1 84.0 96.7 96.0
Innovation provided by a new cancer drug is due to its
improvement on safety
81.2 76.0 88.3 74.0
Innovation provided by a new cancer drug is due to its
improvement on convenience of administration
77.4 72.0 70.0 56.0
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and vomiting. Hair loss had a greater relevance
for healthcare policy makers (40.0%) and
patients (31.7%) compared to oncologists
(15.1%) or the general population participants
(20.0%) (Table 3).
DISCUSSION
In cancer care, value is often understood as
treatment benefits or quality-of-care weighed
against economic cost. Some approaches have
been developed in order to define the value of
new cancer drugs. The conceptual framework
proposed by ASCO is based on clinical benefits
(efficacy), toxicity (safety) and cost [8], while
ESMO-MCBS is mainly based on the magnitude
of clinical benefit, QoL and toxicity [9]. Despite
these approaches, value considerations may
differ among stakeholders. The results of this
study, that aimed to explore the main factors
that drive innovation in oncology from
different perspectives, revealed that gains in
QoL, survival, safety, cost and innovation are
perceived differently by different groups of
stakeholders. For example, although
improvements in QoL are considered an
important added value for new cancer drugs
by all the respondents, there were differences
among participants regarding the value
assigned to QoL when compared to survival.
Differences were also observed related to
economic factors and safety. Healthcare policy
makers gave greater importance to the
economic impact related to oncology
treatment costs than other participants.
Compared with other participants, a higher
proportion of patients agreed to select a
treatment that provides additional survival
despite increasing the risk of side effects.
Similar results are described in other studies.
In the United States, study findings revealed
that oncologists value length of survival highly
compared to improvements in QoL when taking
chemotherapy decisions [14]. A study
conducted in Israel identified differences in
the perception of the value of cancer health
among family physicians and oncologists [15].
Family physicians valued life-prolonging and
QoL-enhancing interventions roughly equally,
while oncologists valued interventions that
extended survival highly compared with those
that improved only QoL. It has been suggested
that these findings may have important
implications in the coverage and
reimbursement decisions of new cancer
treatments [14, 16]. Although achieving gains
in survival was considered highly important
among all participants, healthcare policy
makers demanded a greater survival
improvement, compared to the other
respondents, in order to justify the added
value of an innovative cancer treatment.
With regard to cancer drug cost, some
studies had reported that cancer patients are
largely desensitized to the cost of their
treatment, mainly because of their insurance
Table 2 continued
Statement % of participants stating ‘‘I agree’’ or ‘‘I absolutely agree’’
Oncologist
(n 5 53)
Healthcare
policy maker
(n5 25)
Patients
(n5 60)
General
population
(n5 50)
Innovation provided by a new cancer drug is due to the
development of strategies aimed at a speciﬁc target
100.0 80.0 93.3 78.0
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coverage, meaning that drug prices are not
significantly constrained by patients’
willingness to pay [17] and in some cases, the
value of treatment exceeds the total amount
paid by them and their insurer [18]. However,
nowadays, mainly due to the economic
sustainability of health system has become a
cornerstone of global economic policies, this is
changing. The rising cost of cancer drugs is
creating unintended financial consequences for
patients. Cancer patients must face potential
financial stresses related to out-pocket
expenditures (medical or non-medical
expenses), loss of earnings (patient and
relatives), being increasingly more concerned
about cancer drug cost [19, 20].
In line with our results that showed that all
participants agree that patients should receive
information regarding the budgetary impact of
cancer treatment, even though they do not
have to pay for it, some studies conclude that
many clinicians consider that cost information
should be shared with patients rather than
making clinical recommendations based on
cost without patients’ input [21].
A review that aims to identify and compare
the preferences of patients, the general public
and payers to determine the values that should
shape public funding decisions for new cancer
drugs, suggests that payers consider many
factors and prioritize efficiency in funding
decisions, while patients and the general
public consider fewer factors and prioritize
access to cancer treatments with the potential
to save or extend life [9].
Finally, as per the safety of new cancer drugs,
a recent study that aimed to investigate the
attitudes of physicians, healthy control subjects
and melanoma patients towards a specific drug
showed that patients strived for a longer life
regardless of the side effects and tumor response
rates, whereas physicians were reluctant to use
therapies with a higher incidence of side effects
and marginal cancer response benefits [22].
These findings need to be understood in the
context of sample biases and ambit of the study.
Table 3 Importance of the side effects for the 4 groups of participants (in bold the three adverse events with higher values)
Side effects n (% participants)
Oncologist
(n5 53)
Healthcare policy
maker (n5 25)
Patients
(n5 60)
General population
(n5 50)
Nausea 9 (17.0) 4 (16.0) 7 (11.7) 6 (12.0)
Vomiting 29 (54.7) 7 (28.0) 20 (33.3) 16 (32.0)
Pain 42 (79.2) 21 (84.0) 41 (68.3) 41 (82.0)
Fatigue 11 (20.8) 2 (18.0) 15 (25.0) 10 (20.0)
Dizziness 5 (9.4) 0 (0) 6 (10.0) 10 (20.0)
Hair loss 8 (15.1) 10 (40.0) 19 (31.7) 10 (20.0)
Diarrhea 7 (13.2) 3 (12.0) 9 (15.0) 8 (16.0)
Serious infections due to
compromised immune system
43 (81.0) 20 (80.0) 46 (76.7) 40 (80.0)
Rash 1 (1.9) 6 (24.0) 10 (16.7) 9 (18.0)
Others 1 (1.9) 2 (8.0) 7 (11.7) 0 (0)
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A convenience sample of general population
was used, not being representative of the
general population. Even though the sample
size of the study is not very large, there is a vast
range of sample sizes used in qualitative studies,
with the most common sample size being
between 20 and 30 interviews [10]. Further
research is needed to establish the magnitude of
meaningful differences in the views of cancer
treatment innovation in the Spanish Health
System.
This study describes an overall view of the
similarities and differences in the gains in drug
safety, QoL, survival, compliance with patients’
clinical characteristics and costs as a means of
evaluating the perception of the added value of
a new cancer treatment by different
stakeholders in Spain. The differences observed
in the study highlight the need to consider the
perspective of different stakeholders in the
assessment of a new cancer drugs to obtain
more informed decisions when deciding on the
most appropriate treatment to use, and
contribute to the debate on the definition of
the value of innovation in oncology addressing
the different perspectives.
CONCLUSION
In conclusion, since QoL, survival, safety, cost
and innovation are perceived differently by
stakeholders, this should be considered during
the assessment of a new cancer drug.
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